Company news

Mauna Kea Technologies SA news in 2026

Mauna Kea Technologies SA's news releases, calls and decks from 2026, newest first.

View company

Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates

October 19, 2026

Mauna Kea Technologies Announces 2026 Half-Year Results

October 7, 2026

Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

October 6, 2026

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer

August 26, 2026

Mauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capital

August 7, 2026

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts

July 28, 2026

Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth

July 21, 2026

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

July 16, 2026

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

July 15, 2026

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

June 4, 2026

Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying "Triple Healing", a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis

June 3, 2026

Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation

May 20, 2026

Mauna Kea Technologies Announces Nomination of 3 New Directors

May 18, 2026

AGM 2026 – Resolutions

May 11, 2026

AGM 2026 – Candidate Profiles

May 11, 2026

AGM 2026 – Notice of Meeting for Registered Shareholders

May 11, 2026

AGM 2026 – Board’s Report on Resolutions

May 11, 2026

2025 Annual Financial Report (free translation)

May 11, 2026

Mauna Kea Technologies: Publication of the 2025 Annual Financial Report

April 30, 2026

Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio® To Be Presented at Digestive Disease Week® 2026

April 28, 2026

Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025

April 22, 2026

Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth

April 15, 2026

Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

April 8, 2026

Mauna Kea Technologies Updates Its Financial Calendar

March 17, 2026

Mauna Kea Technologies Announces Major Milestone for Cellvizio® in Pancreatic Cysts with CLIMB Study Selected for ASGE Presidential Plenary Session at DDW 2026

March 11, 2026

Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom

February 23, 2026

Mauna Kea Technologies Announces CE MDR Certification For Cellvizio® and Its Associated Probes

February 10, 2026

Mauna Kea Technologies Announces New Commercial Organization to Accelerate Growth Outside the United States

February 4, 2026

Mauna Kea Technologies Announces Initiation of Coverage by Allinvest Securities

January 26, 2026

Mauna Kea Technologies Announces Its 2026 Financial Calendar Highlighted by Its Participation in Several Investor Forums

January 21, 2026

Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S.

January 15, 2026

Decks in 2026